Skip to main content
OpenTrials
Completed

NCT Number: NCT01902017

Investigations of Mechanisms and Treatment in Post-traumatic Joint Contractures

Injured joints, especially at the elbow, are at risk for permanent motion loss, also known as joint contractures. Joint contractures limit the function of an elbow and are a recognized complication that occurs often after a traumatic injury. The benefits of early motion after injury has helped in preventing joint contractures but there are still several patients that develop debilitating joint contractures. Current research suggests that mast cells, which are found in the joint, are key in causing joint contractures. Research has been done using a medication called Ketotifen. Ketotifen has been linked to stabilizing mast cells and preventing the joint contracture. It is hoped that short-term use of this medication after an injury will prevent the contracture from occurring.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Foothills Medical Centre, Calgary, Alberta, Canada

Loading trial locations.

About this study

Individuals ≥ 18 years old with isolated distal 1/3 humerus and/or proximal 1/3 ulna and/or proximal 1/3 radius fractures and/or elbow dislocations (open fractures with or without nerve injury may be included) and presented to Peter Lougheed Centre (PLC), Foothills Medical Center (FMC), or South Health Campus (SHC).

Participants were required to take Ketotifen 5mg by mouth twice a day for 6 weeks or placebo twice a day by mouth for 6 weeks. Neither the participant nor the physician knew if the participant was taking Ketotifen or placebo. Sometimes this type of injury requires surgery. This study invited both patients that do and do not require surgery to participate.

We took a sample of blood to measure tryptase (normally found in the body). We predicted people with high levels of tryptase were more likely to develop stiffening in the joint.

Participants were asked to return for follow up visits 2, 6, 12, 24, and 52 weeks after surgery or date of initial injury if surgery was not required. These visits were part of normal care for this type of injury.

At the visit participants were asked to do the following, some of which was not part of normal care.

At each visit: Range of motion of the elbow was assessed, DASH score was completed- form helping the research group understand the level of disability from this injury, X-rays until the fracture was considered healed (this was normal treatment), SF12 - questionnaire about how the patient was feeling and coping with their injury, Additional information was collected about how the injury was healing and weight was measured.

The participant was required to have physiotherapy which is normal treatment for this injury.

The participant was contacted by telephone at week 1, 3, 4 and 5 while taking the study medication. During these times:

The participant was asked about:

  • any problems with the study medication
  • any new conditions or concerns that have developed

The participant was reminded:

  • of next visit
  • to continue to take study drug as instructed

During these telephone contacts, if any problems were detected that could not be rectified or figured out during the telephone interview, then participant was asked to attend the Cast Clinic to see their doctor in person.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old
  • Isolated distal 1/3 humerus fractures
  • Proximal 1/3 ulna fractures
  • Proximal 1/3 radial fractures
  • Elbow dislocations
  • Open fractures with or without nerve injury
  • Presentation to Peter Lougheed Centre (PLC), Foothills Medical Centre (FMC) or South Health Campus (SHC).

Exclusion criteria

  • Pre-existing elbow contracture
  • Osteoarthritis of affected elbow
  • Inflammatory arthritis of affected elbow
  • Gout of affected elbow
  • Nonspecific monoarticular arthritis of the affected elbow
  • Inability to give informed consent due to irreversible cognitive disorder
  • Inability to comply with post-operative physiotherapy
  • Injury > 7 days at the time of presentation
  • Inability to mobilize elbow injury within 2 weeks of injury or surgery
  • Pregnancy
  • Breast feeding
  • Oral hypoglycemic medications
  • History of epilepsy
  • Lactose intolerance

Treatment and study plan

Ketotifen

Drug

5 mg PO bid

Other names: Zaditen

Placebo

Drug

5 mg placebo PO bid

Other names: Lactose Placebo

Primary outcomes

  1. Joint range of motion

    Time frame: 12 months post-injury

    Extension-flexion arc of motion

Secondary outcomes

  1. Range of motion

    Time frame: 2,6,12,24 and 52 weeks post injury

  2. Patients requiring (re)operation for elbow-related causes

    Time frame: 12 months

  3. Radiographic evaluation for fracture healing/non-union

    Time frame: 12-52 weeks

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Collaborators

  • American Society for Surgery of the Hand
  • Canadian Institutes of Health Research (CIHR)
  • Workers' Compensation Board, Alberta

Registry information

Official study title

Randomized, Double Blind, Placebo Controlled Trial of Ketotifen in Patients With Elbow Fractures or Dislocations

Acronym: Ketotifen

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Jul 17, 2013
Registry last updated
Mar 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.